BioXcel Gets First Approval With Igalmi For Neuropsychiatric Agitation
Executive Summary
Sublingual film product Igalmi is approved to treat agitation related to schizophrenia and bipolar disorder, but BioXcel also is targeting a bigger market opportunity in Alzheimer’s dementia.
You may also be interested in...
PBM Formulary Exclusions On The Rise, PhRMA Says
According to a report commissioned by PhRMA, the three largest pharmacy benefit managers continue to exclude more drugs from standard formularies, including those with expedited FDA approval.
Finance Watch: Blackstone Closes $1.6bn Fund To Back Commercial-Stage Companies
Public Company Edition: Blackstone Life Sciences Yield will finance approved products, while the firm’s prior fund supports late-stage programs. Also, Coeptis will merge with a SPAC, Bausch + Lomb secured post-IPO debt, and BioXcel revealed a $260m financing and new subsidiary.
Keeping Track: Vijoice, Igalmi Approvals Show New Faces Of Older Drugs; Facility Change Extends Vutrisiran Goal
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker